Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | UBE2M | P61081 | 4/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | WRN | Q14191 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199797 | 0.82 | LMNA (0.57) | LMNAARKDRTP53MAPT | |
| SCHEMBL30158523 | 0.82 | LMNA (0.57) | LMNAAR | |
| SCHEMBL4731094 | 0.82 | LMNA (0.57) | LMNAAR | |
| SCHEMBL2704052 | 0.82 | LMNA (0.57) | LMNAARKDRTP53MAPT | |
| SCHEMBL13199794 | 0.82 | LMNA (0.57) | LMNAARKDRTP53MAPT | |
| SCHEMBL202481 | 0.82 | LMNA (0.57) | LMNAAR | |
| SCHEMBL13216335 | 0.82 | LMNA (0.57) | LMNAAR | |
| SCHEMBL4732504 | 0.81 | AR (0.61) | LMNAAR | |
| SCHEMBL14086872 | 0.81 | AR (0.61) | LMNAAR | |
| SCHEMBL13695984 | 0.81 | AR (0.61) | LMNAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118663-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS, INC | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118663-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, FSHR, UBE2V1 | LMNA 804/4885AR 1/4885GRM4 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.